Blog

RXO Inc. RXO is entering a more constructive freight cycle, with tightening capacity and rising contract rates starting to lift unit economics. AI-driven automation and a leaner cost structure add a

Herc Holdings HRI is grappling with significant challenges that are adversely affecting its performance. Escalated operating expenses and a weak macro environment are major headwinds, straining the

Companies operating in the Zacks Utility - Electric Power industry generate, transmit and distribute electricity to millions of customers across the United States. The industry's regulated business

Ouster, Inc. OUST has long been known as a lidar company. But the StereoLabs acquisition has transformed it from a hardware vendor to an end-to-end perception platform.

For years, Ouster built its

Oracle ORCL is scheduled to report its fourth-quarter fiscal 2026 results on June 10.For the fourth quarter of fiscal 2026, revenues are expected to grow from 18% to 20% in constant currency (cc)

The tenuous ceasefire between Iran and the United States has revived uncertainty in financial markets. Crude oil prices have experienced significant swings in response to developments surrounding

Investors in S&P Global Inc. SPGI need to pay close attention to the stock based on moves in the options market lately. That is because the Sept. 18, 2026 $270 Call had some of the highest implied

AbbVie ABBV stock has risen roughly 12% over the past month. A key catalyst behind the increase was the company’s robust first-quarter 2026 report. It beat estimates for both earnings and sales and

The artificial intelligence (AI) boom is creating massive demand for data centers. But powerful AI servers generate enormous amounts of heat, making advanced cooling systems just as important as the

USA Rare Earth, Inc. USAR is advancing its growth strategy with the successful commissioning of Phase 1a of its commercial magnet production line at its Stillwater, OK, facility. The milestone marks

Investors in Merit Medical Systems, Inc. MMSI need to pay close attention to the stock based on moves in the options market lately. That is because the July 17, 2026 $90 Call had some of the highest

Enterprise Products Partners EPD units are trading close to their 52-week high of $40.17, closing at $37.81 on June 5. Over the past year, the EPD stock has gained 19.2%, outperforming the industry’

Investors in KKR Real Estate Finance Trust Inc. KREF need to pay close attention to the stock based on moves in the options market lately. That is because the July 17, 2026 $15.00 Call had some of

Marsh & McLennan Companies, Inc. MRSH is well positioned for growth, driven by product innovation, expansion into emerging markets and strategic acquisitions.

Marsh — with a market capitalization of

Honeywell International Inc. HON has taken a major step toward separating its Aerospace business. The spinoff is scheduled to be completed on June 29, 2026, after which Honeywell Aerospace will

Shares of Markel Group Inc. MKL have declined 15.4% year-to-date compared with the industry’s fall of 5.4%.

Investment portfolio losses, lower premium volume and earnings estimate cuts are pushing

Altimmune ALT is trying to ride a clear shift in liver drug development. Programs are increasingly designed to hit multiple pathways at once, rather than relying on a single lever like weight loss

Zacks Investment Research has recently initiated coverage of Kingsway Corporation KWY, assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook for

Abercrombie & Fitch Co. ANF continues to find strength in its largest market, with the Americas region serving as a key driver of growth amid a challenging global retail environment. While

Altimmune ALT is building its investment case around a single clinical asset with multiple shots on goal in liver disease. Pemvidutide sits at the center of that thesis, with mid-stage data in

Alto Ingredients, Inc. ALTO reported a strong financial turnaround in the first quarter of 2026, driven in large part by the strength of its export business. Despite operating in a seasonally weak

Shares of Corcept Therapeutics CORT have risen 41.8% in the past month, driven by encouraging progress with its proprietary, selective cortisol modulator, relacorilant, which is being developed for

Independent Bank (IBCP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

Bionano Genomics, Inc. (BNGO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings